Novo Holdings Creates New Rare Bleeding Disorder Company, Hemab

  • Funded through Novo Seeds’ company creation and building efforts
  • Focus on rare underserved bleeding disorders with large unmet need
  • Brings together a strong industrial R&D team with deep expertise in hemophilia and clinically validated technologies from Novo Nordisk and Genmab A/S

Novo Seeds, the early stage investment and company creation team of Novo Holdings, announced today that it has invested in a new portfolio company Hemab ApS (Hemab), which is focused on the development of bispecific antibodies for the treatment of rare bleeding disorders.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...